The Sanofi and AstraZeneca drug could compete against Abrysvo, a maternal RSV vaccine from Pfizer. This vaccine is administered to the mother, whose immune system produces antibodies against RSV .

Parents of young babies are anxiously waiting to find out how and where they’ll be able to get their children shots of Sanofi’s new monoclonal antibody that protects against RSV, or ...

The CDC has announced limited availability of Sanofi immunization Beyfortus for RSV prevention in infants. Here's what parents should know to keep babies safe.

Sanofi is speeding up shipping its respiratory syncytial virus (RSV) preventative antibody Beyfortus to get ahead of what it believes will be strong demand in the 2025–26 season.

French multinational pharmaceutical company Sanofi has commenced the shipping of BEYFORTUS (nirsevimab-alip) to the US, targeting both private healthcare providers and the Centers for Disease ...

Sanofi expects infant RSV shot to roll out before respiratory virus season this fall By Spencer Kimball,CNBC • Published July 21, 2023 • Updated on July 22, 2023 at 10:48 am ...

Sanofi and AstraZeneca are closing in on EU approval of nirsevimab, their long-acting antibody for the protection of newborns and infants from respiratory syncytial virus (RSV) infections. The EMA ...

Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season . Paris, June 9, 2025. Sanofi is shipping Beyfortus (nirsevimab) starting in ...

Medical experts in India are calling for urgent attention to Respiratory Syncytial Virus (RSV), a highly contagious but under-discussed cause of lower respiratory tract infections in infants ...

Sanofi (ENXTPA:SAN) has recently announced it will begin shipping Beyfortus in early Q3 2025. This move aims to support healthcare providers ahead of the RSV season. Sanofi's commitment to ...

With trial win, Merck's RSV antibody clesrovimab looks poised to take on Sanofi and AZ's Beyfortus By Kevin Dunleavy Oct 17, 2024 6:00pm Merck & Co. RSV Beyfortus AstraZeneca ...

Merck's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus, which was in short supply nationwide during the 2023 RSV season due to unprecedented ...